Anzeige
Mehr »
Login
Freitag, 10.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0X8Y3 | ISIN: US56035L1044 | Ticker-Symbol: 13M
Tradegate
09.01.25
20:49 Uhr
56,49 Euro
+0,18
+0,32 %
1-Jahres-Chart
MAIN STREET CAPITAL CORPORATION Chart 1 Jahr
5-Tage-Chart
MAIN STREET CAPITAL CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
56,1956,4309.01.
56,1156,5009.01.
PR Newswire
69 Leser
Artikel bewerten:
(0)

Main Street Capital Corporation: Main Street Announces Fourth Quarter 2024 Private Loan Portfolio Activity

Finanznachrichten News

HOUSTON, Jan. 9, 2025 /PRNewswire/ -- Main Street Capital Corporation (NYSE: MAIN) ("Main Street") is pleased to announce the following recent activity in its private loan portfolio. During the fourth quarter of 2024, Main Street originated new or increased commitments in its private loan portfolio of $123.4 million and funded total investments across its private loan portfolio with a cost basis totaling $108.0 million.

The following represent notable new private loan commitments and investments during the fourth quarter of 2024:

  • $42.3 million in a first lien senior secured loan, $8.5 million in a first lien senior secured revolver and $12.7 million in a first lien senior secured delayed draw loan to a provider of janitorial services for the food distribution and grocery end markets;

  • $31.6 million in a first lien senior secured loan, $5.0 million in a first lien senior secured revolver, $5.0 million in a first lien senior secured delayed draw loan and $1.4 million in equity to a distributor of maintenance and repair parts for the industrial, manufacturing and automotive end markets; and

  • Increased commitment of $11.2 million in an incremental first lien senior secured loan to a provider of dietary supplements and other natural solutions focused on gut health.

As of December 31, 2024, Main Street's private loan portfolio included total investments at cost of approximately $2.0 billion across 91 unique borrowers. The private loan portfolio, as a percentage of cost, included 95.4% invested in first lien debt investments and 4.6% invested in equity investments or other securities.

ABOUT MAIN STREET CAPITAL CORPORATION

Main Street (www.mainstcapital.com) is a principal investment firm that primarily provides customized long-term debt and equity capital solutions to lower middle market companies and debt capital to private companies owned by or in the process of being acquired by a private equity fund. Main Street's portfolio investments are typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. Main Street seeks to partner with entrepreneurs, business owners and management teams and generally provides customized "one-stop" debt and equity financing alternatives within its lower middle market investment strategy. Main Street seeks to partner with private equity fund sponsors and primarily invests in secured debt investments in its private loan investment strategy. Main Street's lower middle market portfolio companies generally have annual revenues between $10 million and $150 million. Main Street's private loan portfolio companies generally have annual revenues between $25 million and $500 million.

Main Street, through its wholly owned portfolio company MSC Adviser I, LLC ("MSC Adviser"), also maintains an asset management business through which it manages investments for external parties. MSC Adviser is registered as an investment adviser under the Investment Advisers Act of 1940, as amended.

Contacts:
Main Street Capital Corporation
Dwayne L. Hyzak, CEO, [email protected]
Ryan R. Nelson, CFO, [email protected]
713-350-6000

Dennard Lascar Investor Relations
Ken Dennard / [email protected]
Zach Vaughan / [email protected]
713-529-6600

SOURCE Main Street Capital Corporation

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.